Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound pubescent angelica and indometacin
- Development stage
- Unknown
- Lead developer
- Fangsheng Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Compound Pubescent Angelica and Indometacin (known in China as Fufang Duhuo Yinduomeixin) is a traditional Chinese medicine-Western medicine hybrid combination drug. It is formulated as an oral capsule containing a mixture of traditional Chinese herbal extracts—including Duhuo (Radix Angelicae Pubescentis), Qianghuo (Radix et Rhizoma Notopterygii), Mugua (Fructus Chaenomelis), and Niuxi (Radix Achyranthis Bidentatae)—alongside the nonsteroidal anti-inflammatory drugs (NSAIDs) indomethacin and piroxicam. Developed by Hainan Boda Pharmaceutical (later acquired by Fangsheng Pharmaceutical), this combination is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and various acute and chronic musculoskeletal pain conditions. It exerts its therapeutic effects by combining the wind-dampness dispelling and circulation-promoting properties of the herbal components with the potent cyclooxygenase (COX) inhibition and anti-inflammatory actions of indomethacin and piroxicam.
- Brand names
- JinguzhuangLongdan博龙珑丹珑丹金古壮
- Other names
- Compound Pubescent Angelica and IndometacinCompound Pubescent Angelica and Indometacin CapsulesFufang Duhuo YinduomeixinFufang Duhuo Yinduomeixin CapsulesFufang Duhuo Yinduomeixin Jiaonangduhuo + indomethacin龙胆风湿胶囊
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on compound pubescent angelica and indometacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound pubescent angelica and indometacin.